Topical voriconazole as a novel treatment for fungal keratitis

William Sponsel, Nancy Chen, Demi Dang, Gianmarco Paris, John Graybill, Laura K. Najvar, Lei Zhou, Kwok Wai Lam, Randolph Glickman, Frank Scribbick

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Paecilomyces lilacinus is a fungal pathogen which is generally resistant to amphotericin B and certain other antifungals and is an uncommon cause of devastating fungal keratitis. In the present studies, we evaluated topical voriconazole as therapy for P. lilacinus keratitis in rabbits. Thirty eyes of 15 rabbits were studied. In five animals, the uninfected left eye was treated twice daily with voriconazole (drug control, uninfected eye). In these same animals, the right eye was infected with P. lilacinus but not treated with voriconazole (infection control eye). By day 5, the infection controls had lesions of >2.4 mm in diameter, with conjunctivitis and severe hypopyon, and were sacrificed. In the other 10 rabbits (voriconazole treatment), the right eyes were infected with P. lilacinus and treated with voriconazole beginning on day 3 after infection. Voriconazole therapy caused lesions to decrease during 8 days of therapy, after which rabbits were sacrificed (11 days postinfection). Hyphal masses were present in the control infected eyes and absent in treated infected eyes. Voriconazole was detected in all tissues of treated eyes. Topical voriconazole is effective treatment for P. lilacinus experimental keratitis, and it penetrates more deeply than the corneal tissue.

Original languageEnglish (US)
Pages (from-to)262-268
Number of pages7
JournalAntimicrobial agents and chemotherapy
Issue number1
StatePublished - Jan 2006

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Topical voriconazole as a novel treatment for fungal keratitis'. Together they form a unique fingerprint.

Cite this